Osolac Oral Solution
By Osolac
100ml Oral Solution in a Bottle

Composition
Lactulose(10gm/15ml)

Manufacturer - Biochem Pharmaceutical Industries
BIOCHEM PHARMA, LG 113 / A, Xth Central Mall, Mahavir Nagar, 90ft Road, Next to D Mart, Kandivali - West, Mumbai - 400067.

Expires on or after
November, 2026

liver
Osolac Oral Solution appears to be safe for use in individuals with liver disease based on limited available data. It is suggested that dose adjustment may not be necessary for patients with liver issues. However, it is always recommended to consult with your doctor if you have existing liver impairment or any related concerns before using Osolac Oral Solution. Your doctor can provide proper guidance tailored to your specific health needs.

kidney
Osolac Oral Solution may be safe for individuals with kidney disease; dose adjustment may not be necessary. Consult your doctor if you have kidney impairment or concerns.

alcohol
When taking Osolac Oral Solution, there are no harmful effects from drinking alcohol. Consult your doctor if you have concerns about how alcohol may impact Osolac Oral Solution.

driving
When using Osolac Oral Solution, it typically does not impact your driving ability based on a 100 ml dose.

pregnancy
Osolac Oral Solution is generally safe during pregnancy based on animal studies. Limited human studies advise consulting a doctor before use, especially in the first trimester. Use caution and seek medical advice for Osolac Oral Solution during pregnancy.

breastfeeding
Osolac Oral Solution appears safe during breastfeeding, with minimal risk to the baby based on limited data. Consult your doctor before using Osolac Oral Solution while breastfeeding, ensuring benefits outweigh potential risks.
Habit Forming | No |
Chemical Class | Synthetic Disaccharide |
Therapeutic Class | GASTRO INTESTINAL |
Action Class | Osmotic laxatives/Purgative |
₹129.15
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 01-Oct-2024